{
    "nct_id": "NCT03317899",
    "official_title": "A Randomized Controlled Trial Evaluating the Use of G-CSF After Plerixafor-Mobilized Autologous Stem Cell Transplant (Auto HSCT)",
    "inclusion_criteria": "* Undergoing autologous stem cell transplant for one of the following diagnoses:\n\n  * Multiple myeloma\n  * Non-Hodgkin lymphoma\n* Karnofsky performance status of >= 70%\n* Patients must meet the Thomas Jefferson University Hospital (TJUH) bone marrow transplant (BMT) standard of procedure (SOP) guidelines for \"Patient Criteria for Autologous HSCT\"\n* Left ventricular ejection fraction (LVEF) of â‰¥ 40%\n* Adjusted Carbon monoxide diffusing capability (DLCO) > 45% of predicted corrected for hemoglobin\n* Serum bilirubin < 1.8\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 X upper limit of normal\n* Serum creatinine =< 2.0 mg/dl and/or creatinine clearance of > 40 ml/min (excludes multiple myeloma patients receiving high dose melphalan conditioning)\n* Willingness to use contraception if childbearing potential\n* Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process\n* Life expectancy of > 12 months (exclusive of the disease for which the auto HSCT is being performed)\n* Patients must have undergone stem cell mobilization with the combination of G-CSF and plerixafor as per TJUH BMT SOP guidelines\n* Collection of an adequate number of CD34+ stem cells, i.e. >= 4-6 x 10^6/kg from apheresis\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled human immunodeficiency virus (HIV)\n* Uncontrolled bacterial infection\n* Active central nervous system (CNS) disease\n* Pregnancy or lactation\n* Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment",
    "miscellaneous_criteria": ""
}